Healthy Female Army
No Result
View All Result
  • Healthcare
  • Health and Medicine
  • Health News
  • Staying Healthy
  • Healthcare
  • Health and Medicine
  • Health News
  • Staying Healthy
No Result
View All Result
Healthy Female Army
No Result
View All Result
Home Healthcare

FDA pauses authorization for last remaining COVID-19 monoclonal antibody treatment

by
November 30, 2022
in Healthcare
0
FDA pauses authorization for last remaining COVID-19 monoclonal antibody treatment
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

The Food and Drug Administration (FDA) said on Wednesday that the COVID-19 monoclonal antibody treatment bebtelovimab from Eli Lilly is no longer authorized for emergency use in the U.S. as it is not expected to be effective at neutralizing the two most dominant omicron subvariants in the country right now.

The omicron subvariants BQ.1 and BQ.1.1 collectively account for 57.3 percent of COVID-19 cases in the U.S. right now, having pushed the BA.5 omicron subvariant out as the dominant subvariant earlier this month.

“Given that a COVID-19 infection is likely to be caused by a non-susceptible SARS-CoV-2 variant, and consistent with the terms and conditions of the Letter of Authorization, bebtelovimab is not currently authorized for emergency use in any U.S. region at this time,” the FDA said in a statement.

The agency stated that Eli Lilly and its distributors have paused distribution of bebtelovimab until further notice and the Administration for Strategic Preparedness and Response has also paused the fulfillment of any pending requests for the drug.

For the moment, the FDA is recommending that remaining supplies of bebtelovimab be retained in case a variant that is susceptible to the drug becomes more prevalent in the U.S. in the future.

“Lilly and the FDA agree that it is not medically appropriate, at this time, to treat high-risk patients with mild-to-moderate COVID-19 with bebtelovimab in the US,” Eli Lilly said in a statement, confirming that its monoclonal antibody treatment does not appear to neutralize the BQ.1 and BQ.1.1 subvariants.

“Lilly continually monitors the global COVID-19 environment, assessing the neutralization activity of potential antibody therapies against a wide array of existing and emerging mutations and variants,” said the company. “Lilly will continue to search and evaluate monoclonal antibodies to identify potential candidates for clinical development against new variants.”

Monoclonal antibodies function by mimicking natural antibodies produced by the immune system, limiting how much a virus can replicate inside a person’s body. Before vaccines and treatments were available, monoclonal antibodies were one of the only treatments available for COVID-19 infections.

In 2020, former President Trump was given a round of monoclonal antibodies when he was hospitalized with COVID-19, later calling the treatment a “miracle.”

With this treatment no longer being distributed or authorized for use, the FDA advised that health care providers choose “appropriate” treatments including the authorized antivirals Paxlovid, Veklury and Lagevrio.

The agency also recommended the use of convalescent plasma — taken from the blood of people who have recovered from COVID-19 infections — for patients who have compromised immune systems.

Previous Post

GOP governors, senators take aim at Pentagon COVID-19 vaccine mandate

Next Post

CDC starting wastewater testing for polio in select communities

Next Post
CDC starting wastewater testing for polio in select communities

CDC starting wastewater testing for polio in select communities

  • Trending
  • Comments
  • Latest
Vaccine protection against COVID-19 related issues

Vaccine protection against COVID-19 related issues

April 26, 2022
2 in 3 physicians concerned about AI driving diagnosis, treatment decisions: Survey

2 in 3 physicians concerned about AI driving diagnosis, treatment decisions: Survey

October 31, 2023
Religious services may lower risk of ‘deaths of despair’

Religious services may lower risk of ‘deaths of despair’

April 26, 2022
Signaling molecule may prevent Alzheimer’s

Signaling molecule may prevent Alzheimer’s

April 26, 2022
GOP leaders looking to expand enhanced Medicaid matching rate to woo Murkowski

GOP leaders looking to expand enhanced Medicaid matching rate to woo Murkowski

0
7 Tips to Make Your Workout Routine More Sustainable

7 Tips to Make Your Workout Routine More Sustainable

0
11 Weight Loss Tips That Will Get you Fast Results

11 Weight Loss Tips That Will Get you Fast Results

0
What are the Sunday Scaries? Plus, Here’s How to Beat Them

What are the Sunday Scaries? Plus, Here’s How to Beat Them

0
GOP leaders looking to expand enhanced Medicaid matching rate to woo Murkowski

GOP leaders looking to expand enhanced Medicaid matching rate to woo Murkowski

July 1, 2025
Another GOP senator warns Medicaid cuts could boomerang on Republicans

Another GOP senator warns Medicaid cuts could boomerang on Republicans

July 1, 2025
Collins, Murkowski vote for motion to help strike defunding of Planned Parenthood from GOP megabill

Collins, Murkowski vote for motion to help strike defunding of Planned Parenthood from GOP megabill

June 30, 2025
DOJ announces takedown of record $14.6B in health care fraud

DOJ announces takedown of record $14.6B in health care fraud

June 30, 2025

Recent News

GOP leaders looking to expand enhanced Medicaid matching rate to woo Murkowski

GOP leaders looking to expand enhanced Medicaid matching rate to woo Murkowski

July 1, 2025
Another GOP senator warns Medicaid cuts could boomerang on Republicans

Another GOP senator warns Medicaid cuts could boomerang on Republicans

July 1, 2025
Collins, Murkowski vote for motion to help strike defunding of Planned Parenthood from GOP megabill

Collins, Murkowski vote for motion to help strike defunding of Planned Parenthood from GOP megabill

June 30, 2025
DOJ announces takedown of record $14.6B in health care fraud

DOJ announces takedown of record $14.6B in health care fraud

June 30, 2025
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Email Whitelisting
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Email Whitelisting

Disclaimer: Healthyfemalearmy.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized beauty advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give health advice or provide beauty recommendation. Any recommendations here should be taken into consideration only after consulting with your doctor.
© 2025 Healthyfemalearmy.com. All rights reserved.

No Result
View All Result
  • Contact Us
  • Email Whitelisting
  • Home 1
  • Privacy Policy
  • Terms and Conditions
  • Terms and Conditions

Disclaimer: Healthyfemalearmy.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized beauty advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give health advice or provide beauty recommendation. Any recommendations here should be taken into consideration only after consulting with your doctor.
© 2025 Healthyfemalearmy.com. All rights reserved.